Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction

Fertility and Sterility

Volumn 91, Issue 4 SUPPL., 2009, Pages 1526-1528

  Cerrillo, Maria ^a   Rodríguez, Sara ^a   Mayoral, Mercedes ^a   Pacheco, Alberto ^a   Martínez Salazar, Javier ^a   Garcia Velasco, Juan A ^a,b  

^a IVI Madrid   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN AGONIST; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MENSTRUAL CYCLE; OOCYTE MATURATION; OVARY FOLLICLE FLUID; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; CELL DIFFERENTIATION; CHORIONIC GONADOTROPIN; COHORT STUDIES; FEMALE; FERTILIZATION IN VITRO; FOLLICULAR FLUID; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEOLYSIS; OOCYTE DONATION; OOCYTES; OOGENESIS; OVARIAN HYPERSTIMULATION SYNDROME; OVUM; PROSPECTIVE STUDIES; SPERM INJECTIONS, INTRACYTOPLASMIC; TRIPTORELIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 63249114848     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.08.118     Document Type: Article

References (16)

1. Navot D., Bergh P.A., and Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 58 (1992) 249-261
2. Balasch J., Fabregues F., and Arroyo V. Peripheral arterial vasodilation hypothesis: a new insight into pathogenesis of ovarian hyperstimulation syndrome. Hum Reprod 13 (1998) 2718-2730
3. McClure N., Healy D.L., Rogers P.A., Sullivan J., Beaton L., and Haning R.V. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344 (1994) 235-236
4. Abramov Y., Barak V., Nisman B., and Schenker J.G. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 68 (1997) 133-137
5. Pellicer A., Albert C., Mercader A., Bonilla-Musoles F., Remohi J., and Simon C. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin (IL)-1β, IL-6, and vascular endothelial growth factor (VEGF). Fertil Steril 71 (1999) 482-489
6. Gomez R., Simon C., Remohi J., and Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 143 (2002) 4339-4348
7. Gomez R., Simon C., Remohi J., and Pellicer A. Administration of moderate and high doses of gonadotropins to female rats incesaes ovarian vascular endomthelial growth factor (VEGF) ans VEGF receptor 1 expression that is asssociated to vascular hypermeability. Biol Reprod 68 (2003) 2164-2171
8. Villasante A., Pacheco A., Pau E., Ruiz A., Pellicer A., and Garcia-Velasco J.A. Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Hum Reprod 23 (2008) 662-667
9. Soares S., Gomez R., Simon C., Garcia-Velasco J., and Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 14 (2008) 321-333
10. Acevedo B., Gómez-Palomares J.L., Ricciarelli M.D., and Hernández E. Triggering ovulation with gonadotropin-releasing hormone agonist does not compromise embryo implantation rates. Fertil Steril 86 (2006) 1682-1687
11. Engmann L., Siano L., Schmidt D., Nulsen J., Maier D., and Benadiva C. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reprod Biomed Online 13 (2006) 639-644
12. Griesenger G., Diedrich K., Devroey P., and Kolibianakis E. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 12 (2006) 159-168
13. Kol S., and Solt I. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?. J Assist Reprod Genet 25 (2008) 63-66
14. Engman L., DiLuigi A., Schmidt D., Nulsen J., Maier D., and Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 89 (2008) 84-91
15. Babayof R., Margalioth E., Huleihel M., Amash A., Zylber-Haran E., Gal M., et al. Serum inhibin A, VEGF and TNFα levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 21 (2006) 1260-1265
16. Asimakopoulos B., Köster F., Felberbaum R., Al-Hasani S., Diedrich K., and Nikolettos N. Cytokine and hormonal profile in blood serum and follicular fluids during ovarian stimulation with the multidose antagonist or the long agonist protocol. Hum Reprod 21 (2006) 3091-3095